Galectin Therapeutics, Inc. (GALT) Analysts See $-0.14 EPS

July 14, 2018 - By Vernon Prom

Galectin Therapeutics, Inc. (NASDAQ:GALT) LogoInvestors sentiment increased to 1.86 in 2018 Q1. Its up 1.33, from 0.53 in 2017Q4. It is positive, as 7 investors sold Galectin Therapeutics, Inc. shares while 7 reduced holdings. 17 funds opened positions while 9 raised stakes. 4.02 million shares or 30.74% more from 3.08 million shares in 2017Q4 were reported.
Optimum Advsrs reported 20 shares or 0% of all its holdings. 319,187 were reported by Eam Investors Llc. Moreover, Schwab Charles Invest Mgmt has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 21,400 shares. Tci Wealth Advisors reported 0% stake. Rathbone Brothers Public Lc holds 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 16,400 shares. Art Ltd owns 0.01% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 57,775 shares. Morgan Stanley owns 44,260 shares or 0% of their US portfolio. Vanguard Grp Incorporated, a Pennsylvania-based fund reported 1.17M shares. 17,450 are owned by State Street. Pnc Svcs owns 51,184 shares or 0% of their US portfolio. Northern Trust holds 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT) or 79,256 shares. Sabby Mgmt has invested 0.08% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Bankshares Of America De has 8,260 shares. Stratos Wealth Prtnrs owns 28,154 shares. California Pub Employees Retirement Sys holds 0% or 23,450 shares in its portfolio.

Since January 25, 2018, it had 3 insider purchases, and 24 sales for $17.06 million activity. 10X Fund – L.P. sold $1.33M worth of stock. Shlevin Harold H. sold $671,988 worth of stock or 115,054 shares. CZIRR JAMES C sold $256,081 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) on Friday, June 1. Shares for $8,191 were bought by FREEMAN KEVIN D. 46,651 shares were sold by CALLICUTT JACK W, worth $233,255. 4,000 shares valued at $14,320 were sold by ZUCCONI THEODORE DANIEL on Monday, April 16.

Analysts expect Galectin Therapeutics, Inc. (NASDAQ:GALT) to report $-0.14 EPS on August, 13.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.14 EPS. After having $-0.12 EPS previously, Galectin Therapeutics, Inc.’s analysts see 16.67 % EPS growth. The stock decreased 1.06% or $0.07 during the last trading session, reaching $6.55. About 359,917 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 77.97% since July 14, 2017 and is uptrending. It has outperformed by 65.40% the S&P500.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $247.20 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: which released: “Galectin Therapeutics IPF Patent Solidifies Platform Technology Status” on July 05, 2018, also with their article: “Mid-Day Market Update: Crude Oil Up Over 3%; Aquinox Pharmaceuticals Shares Plunge” published on June 27, 2018, published: “42 Biggest Movers From Yesterday” on July 06, 2018. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: and their article: “2 Clinical-Stage Biotech Stocks That Could Soar Next Week” published on June 17, 2018 as well as‘s news article titled: “3 Biotech Stocks That Soared This Week: Are They Buys?” with publication date: June 16, 2018.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.